Aurora Cannabis (US) ( (ACB) ) has released its Q1 earnings. Here is a breakdown of the information Aurora Cannabis (US) presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Aurora Cannabis Inc., a prominent player in the global medical cannabis industry, is headquartered in Edmonton, Alberta, and operates across Canada, Europe, Australia, and New Zealand, offering a diverse range of cannabis products for both medical and consumer markets.
In its fiscal 2026 first-quarter results, Aurora Cannabis reported significant growth in its global medical cannabis net revenue, which increased by 37% year-over-year to $64.8 million, with international medical cannabis net revenue rising by an impressive 85% to $37.1 million. The company also achieved a substantial increase in adjusted EBITDA, which grew by over 200% to $10.8 million, and generated positive free cash flow of $9.2 million, marking a 42% year-over-year increase.
Key financial highlights include a total net revenue of $98.0 million, representing a 17% increase from the previous year, driven by strong performance in the global medical cannabis sector. The company’s adjusted gross margin before fair value adjustments improved to 52%, up from 42% in the prior year. Despite a decline in consumer cannabis net revenue, Aurora’s strategic focus on high-margin medical cannabis and plant propagation businesses contributed to its robust financial performance.
Aurora’s management remains optimistic about the future, expecting continued growth in global medical cannabis revenue and improved adjusted gross margins in the upcoming quarters. The company anticipates maintaining positive annual free cash flow for the second consecutive year, underscoring its commitment to operational excellence and strategic differentiation in the competitive cannabis market.